专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2011032174A Medicinal composition containing benzyl phenyl glucopyranoside derivative 审中-公开
标题翻译：含有苯甲酰基苯并呋喃衍生物的药物组合物
公开(公告)号：JP2011032174A
公开(公告)日：2011-02-17
申请号：JP2009177150
申请日：2009-07-30
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： YAMANOI SHIGEO , MORI KAZUKI , IWAMOTO MITSUHIRO , NAKAJIMA ATSUKO , HONDA TAKESHI , IZUMI MASANORI , OGATA TSUNEAKI , OKUYAMA AKIRA
IPC分类号： C07H15/203 , A61K31/7034 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/06 , A61P25/00 , A61P27/02
摘要： PROBLEM TO BE SOLVED: To provide a medicinal composition for treating and/or preventing hyperglycemia, impaired glucose tolerance (IGT), diabetes-related disease or diabetes complication caused by type-1 diabetes, type-2 diabetes, gestational diabetes or another factor, containing a compound having a new structure, exhibiting low side effects and having excellent human SGLT1- and/or SGLT2-inhibiting activities, or a hydrate thereof as an active ingredient. SOLUTION: The medicinal composition contains the compound represented by general formula (I) or the hydrate thereof. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：提供用于治疗和/或预防高血糖，糖耐量异常（IGT），糖尿病相关疾病或由1型糖尿病引起的糖尿病并发症，2型糖尿病，妊娠糖尿病或另一个因素，含有具有新结构的化合物，具有低的副作用并具有优异的人SGLT1和/或SGLT2抑制活性，或其水合物作为活性成分。药物组合物含有通式（I）表示的化合物或其水合物。版权所有（C）2011，JPO＆INPIT

2. 发明专利

JP2009203230A Pharmaceutical composition containing benzyl phenyl glucopyranoside derivative 审中-公开
标题翻译：含有苯甲酰基苯并呋喃衍生物的药物组合物
公开(公告)号：JP2009203230A
公开(公告)日：2009-09-10
申请号：JP2009019088
申请日：2009-01-30
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： HONDA TAKESHI , OGUCHI MINORU , YOSHIDA MASAO , OKUYAMA AKIRA , OGATA TSUNEAKI , ABE MANABU , UEDA KENJIRO , OSUMI JUN , IZUMI MASANORI
IPC分类号： C07H7/04 , A61K31/7034 , A61K31/7056 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/10 , A61P9/10 , A61P9/12 , A61P13/00 , A61P13/12 , A61P19/06 , A61P25/00 , A61P27/02 , A61P31/00 , A61P43/00 , C07H7/06
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing a compound having low adverse effects and exhibiting excellent human SGLT inhibiting activity as an active component and useful for the treatment or prevention of hyperglycemia, glucose intolerance, diabetes-related diseases and diabetic complications caused by type 1 diabetes, type 2 diabetes, pregnancy diabetes and other factors. SOLUTION: The pharmaceutical composition contains a compound expressed by general formula (I) or its pharmacologically allowable salt [in the formula, R 1 is a hydrogen atom, an amino group, a mono or di(1-6C alkyl)amino group, a 1-6C alkyl group, a hydroxy(1-6C alkyl) group or the like; R 2 is a hydrogen atom, a halogen atom or a 1-6C alkyl group; R 3 is a 1-6C alkyl group, a hydroxy(1-6C alkyl) group, a 1-6C alkyl group or the like; R 4 is a hydrogen atom, a 1-6C alkyl group, a 2-7C acyl group, a 1-6C alkoxycarbonyl group or the like; R 5 , R 6 , R 7 and R 8 may be the same or different and each represents a hydrogen atom or a 1-6C alkyl group (wherein, R 5 , R 6 , R 7 and R 8 are not hydrogen atoms at the same time); R 9 is a halogen atom; n is 0-4; and X is CH or N]. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供一种药物组合物，其含有副作用低的化合物，作为活性成分显示优异的人SGLT抑制活性，可用于治疗或预防高血糖，葡萄糖不耐受，糖尿病相关疾病和糖尿病 1型糖尿病，2型糖尿病，妊娠糖尿病等因素引起并发症。解决方案：药物组合物含有由通式（I）表示的化合物或其药理学上允许的盐[在该式中，R“SP”是氢原子，氨基，单或二（1-6C烷基）氨基，1-6C烷基，羟基（1-6C烷基）等; R 2是氢原子，卤素原子或1-6C烷基; R 6是1-6C烷基，羟基（1-6C烷基），1-6C烷基等; R 4是氢原子，1-6C烷基，2-7C酰基，1-6C烷氧基羰基等; R 5 ，R SP 6，R SP 7和/或SP S 8可以相同或不同，并且各自表示氢原子或1-6C烷基（其中，R 6，R 6，R 6，R SP 7，同时不是氢原子）; R 是卤素原子; n为0-4; X为CH或N]。版权所有（C）2009，JPO＆INPIT

3. 发明专利

JP2009108105A Benzyl phenyl glucopyranoside derivative 审中-公开
标题翻译：苄基苯丙酸衍生物
公开(公告)号：JP2009108105A
公开(公告)日：2009-05-21
申请号：JP2009035070
申请日：2009-02-18
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： HONDA TAKESHI , OGUCHI MINORU , YOSHIDA MASAO , OKUYAMA AKIRA , OGATA TSUNEAKI , ABE MANABU , UEDA KENJIRO , OSUMI JUN , IZUMI MASANORI
IPC分类号： C07H15/203 , A61K31/7034 , A61K31/706 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/10 , A61P9/04 , A61P9/10 , A61P9/12 , A61P13/12 , A61P15/00 , A61P19/06 , A61P25/00 , A61P27/02 , A61P27/12 , A61P31/04 , A61P43/00 , C07H17/02
CPC分类号： C07H15/203 , A61K9/2018 , C07H17/02
摘要： PROBLEM TO BE SOLVED: To provide a compound which exhibits excellent inhibitory activity on human SGLT while exhibiting low side effects. SOLUTION: The compound expressed by formula (I) or its pharmacologically acceptable salt, is disclosed [in the formula R 1 is a hydrogen atom, an amino group, a hydroxy 1-6C alkyl group or the like; R 2 is a hydrogen atom or the like; R 3 is a 1-6C alkyl group, a hydroxy 1-6C alkyl group or the like; R 4 is a hydrogen atom, a 2-7C acyl group or the like; R 5 , R 6 , R 7 and R 8 are the same or different, and each a hydrogen atom, a 1-6C alkyl group or the like (where R 5 , R 6 , R 7 and R 8 are not hydrogen atoms at the same time); R 9 is a halogen atom; n is 0 to 4; and X is CH or N]. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供对人SGLT具有优异抑制活性的化合物，同时具有低的副作用。解决方案：式（I）表示的化合物或其药理学上可接受的盐在[R 1 SP 1]中公开是氢原子，氨基，羟基1-6C烷基或类似物; R 2是氢原子等; R 3是1-6C烷基，羟基1-6C烷基等; R 4是氢原子，2-7C酰基等; R 5 ，R 6 ，R 7 和R 8 相同或不同，，1-6C烷基等（其中R SP 5，R SP 6，R SP 7和/或SP SP 8） >同时不是氢原子）; R 是卤素原子; n为0〜4; X为CH或N]。版权所有（C）2009，JPO＆INPIT

4. 发明专利

JP2008214336A Medicine containing cercosporamide derivative 审中-公开
标题翻译：含有酪氨酰胺衍生物的药物
公开(公告)号：JP2008214336A
公开(公告)日：2008-09-18
申请号：JP2008024696
申请日：2008-02-05
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： FURUKAWA AKIHIRO , OSUMI JUN , ARITA TAKESHI , FUKUZAKI TAKEHIRO , ARAKI ICHIJI , MORI MAKOTO , MOMOSE TAKAYUKI , HONDA TAKESHI , KUROBA MASANORI , OKUYAMA AKIRA , SATO SUSUMU
IPC分类号： C07D307/91 , A61K31/343 , A61K31/443 , A61P3/10 , C07D405/12
摘要： PROBLEM TO BE SOLVED: To provide a new cercosporamide derivative which has a good hypoglycemic effect and is useful for a therapeutic drug and/or preventive drug for diabetes, and to provide a therapeutic drug containing a pharmacologically acceptable salt thereof or an ester thereof. SOLUTION: The therapeutic drug contains the cercosporamide derivative represented by general formula (I), and the pharmacologically acceptable salt thereof or an ester thereof. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：待解决的问题：提供一种具有良好的降血糖作用并可用于治疗药物和/或糖尿病预防药物的新的孢子虫素衍生物，并提供含有其药理学上可接受的盐或酯的治疗药物它们。治疗药物含有通式（I）表示的孢子孢子酰胺衍生物及其药理学上可接受的盐或其酯。版权所有（C）2008，JPO＆INPIT

5. 发明专利

JP2008101016A Novel cercosporamide derivative 有权
标题翻译：新西兰酰胺衍生物
公开(公告)号：JP2008101016A
公开(公告)日：2008-05-01
申请号：JP2007306368
申请日：2007-11-27
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： FURUKAWA AKIHIRO , OSUMI JUN , ARITA TAKESHI , FUKUZAKI TAKEHIRO , ARAKI ICHIJI , MORI MAKOTO , MOMOSE TAKAYUKI , HONDA TAKESHI , KUROBA MASANORI , OKUYAMA AKIRA , SATO SUSUMU
IPC分类号： C07D307/91 , A61K31/343 , A61P3/08 , A61P3/10
摘要： PROBLEM TO BE SOLVED: To provide a novel cercosporamide derivative which has a good hypoglycemic effect and is useful for a therapeutic drug and/or preventive drug for diabetes, a pharmacologically acceptable salt thereof or an ester thereof. SOLUTION: The cercosporamide derivative has general formula (I), wherein X represents an oxygen atom or the like and R 1 , R 2 , R 3 and R 4 represent a hydrogen atom or a 1-6C alkyl group or the like, and a pharmacologically acceptable salt thereof or an ester thereof are provided. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：提供一种具有良好的降血糖作用的新颖的孢霉酰胺衍生物，可用于糖尿病的治疗药物和/或预防药物，其药理学上可接受的盐或其酯。解决方案：孢子孢子酰胺衍生物具有通式（I），其中X表示氧原子等，R“SP”2，R“3” 和R 4 表示氢原子或1-6C烷基等，并且提供其药理学上可接受的盐或其酯。版权所有（C）2008，JPO＆INPIT

6. 发明专利

JP2010100548A Medicine containing new amide derivative 审中-公开
标题翻译：含有新型衍生物的药物
公开(公告)号：JP2010100548A
公开(公告)日：2010-05-06
申请号：JP2008271928
申请日：2008-10-22
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KIYOZUKA YOHEI , KURATA HITOSHI , OGATA TSUNEAKI , OKUYAMA AKIRA , ABE MANABU , HARADA ATSUSHI , KONO KEITA
IPC分类号： A61K31/381 , A61K31/426 , A61K31/433 , A61P1/16 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P11/00 , A61P19/02 , A61P19/06 , A61P27/12 , A61P43/00 , C07D277/20 , C07D277/44 , C07D277/56 , C07D285/12 , C07D285/135 , C07D333/36 , C07D333/38
摘要： PROBLEM TO BE SOLVED: To provide a medicine containing a compound having excellent stearoyl CoA desaturase-inhibiting actions or a pharmacologically acceptable salt thereof. SOLUTION: The medicine contains the compound having general formula (I) [wherein, R 1 is a hydroxy group, a 1C-6C alkoxy group, a 2C-6C hydroxyalkoxy group or the like; R 2 is a hydroxy group, a 1C-6C alkoxy group, a 2C-6C hydroxyalkoxy group or the like; R 3 is a hydrogen atom or the like; R 4 is a 6C-10C aryl group which may be independently substituted with one to five groups selected from the group A of substituent groups, or the like; V is a group represented by the formula: -NH- or a single bond; W is a group represented by the formula: -NH- or a single bond; T is a group represented by the formula: =C(R 5 )- or a nitrogen atom; and Q is a group represented by the formula: =C(R 6 )- or a nitrogen atom] or a pharmacologically acceptable salt thereof. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供含有硬脂酰CoA去饱和酶抑制作用优异的化合物或其药理学上可接受的盐的药物。药物含有具有通式（I）的化合物[其中，R SP 1是羟基，1C-6C烷氧基，2C-6C羟基烷氧基等; R 2是羟基，1C-6C烷氧基，2C-6C羟基烷氧基等; R 3是氢原子等; R 6是可以独立地被一至五个选自取代基组A的基团取代的6C-10C芳基等; V是由下式表示的基团：-NH-或单键; W是由下式表示的基团：-NH-或单键; T是由下式表示的基团：= C（R 5 SP 5） - 或氮原子; Q为由式= C（R 6 SP 6）或氮原子表示的基团）或其药理学上可接受的盐。版权所有（C）2010，JPO＆INPIT

7. 发明专利

JP2009019013A New heteroarylpiperidine derivative 审中-公开
标题翻译：新型异丙肾上腺素衍生物
公开(公告)号：JP2009019013A
公开(公告)日：2009-01-29
申请号：JP2007183312
申请日：2007-07-12
申请人： Daiichi Sankyo Co Ltd , 第一三共株式会社
发明人： UTO YOSHIICHI , KIYOZUKA YOHEI , KURATA HITOSHI , OGATA TSUNEAKI , OKUYAMA AKIRA , KONISHI MASAHIRO , KURIKAWA SHINYA , OSUMI JUN
IPC分类号： C07D401/04 , A61K31/501 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P15/08 , A61P27/12 , A61P43/00 , C07D401/14 , C07D409/14 , C07D413/14
摘要： PROBLEM TO BE SOLVED: To provide a heteroarylpiperidine derivative having excellent stearoyl-CoA desaturase inhibition or its pharmacologically acceptable salt. SOLUTION: The heteroarylpiperidine derivative is represented by formula (I) (wherein A is a group represented by the formula: -CONHR 1 or a group represented by the formula -ER 2 ; R 3 is hydrogen or the like; R 4 is hydrogen or the like; R 5 is a 6-10C aryl group which may be independently substituted with 1 to 5 substituents or the like; R 6 is hydrogen or a halogen; V is nitrogen or the like; W is nitrogen or the like; Y is a carbonyl group or the like; m is 0, 1 or 2; and n is 0, 1 or 2) and includes its pharmacologically acceptable salt. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供具有优异的硬脂酰-CoA去饱和酶抑制的杂芳基哌啶衍生物或其药理学上可接受的盐。解决方案：杂芳基哌啶衍生物由式（I）表示（其中A是由下式表示的基团-CONHR 1或由式-ER 2表示的基团< / SP>; R 3为氢等; R 4为氢等; R 6为6-10C芳基其可以独立地被1至5个取代基等取代; R 6是氢或卤素; V是氮等; W是氮等; Y是羰基或类似; m为0,1或2; n为0,1或2），并且包括其药理学上可接受的盐。版权所有（C）2009，JPO＆INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式